Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Change in Cash (2019 - 2025)

Historic Change in Cash for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to $1.6 million.

  • Cyclerion Therapeutics' Change in Cash rose 19102.56% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 12719.69%. This contributed to the annual value of -$4.3 million for FY2024, which is 2533.13% up from last year.
  • Cyclerion Therapeutics' Change in Cash amounted to $1.6 million in Q3 2025, which was up 19102.56% from -$633000.0 recorded in Q2 2025.
  • Over the past 5 years, Cyclerion Therapeutics' Change in Cash peaked at $25.1 million during Q2 2021, and registered a low of -$13.0 million during Q1 2021.
  • Its 5-year average for Change in Cash is -$2.8 million, with a median of -$1.7 million in 2024.
  • Data for Cyclerion Therapeutics' Change in Cash shows a peak YoY increase of 33623.88% (in 2021) and a maximum YoY decrease of 18549.59% (in 2021) over the last 5 years.
  • Over the past 5 years, Cyclerion Therapeutics' Change in Cash (Quarter) stood at -$8.5 million in 2021, then grew by 17.78% to -$7.0 million in 2022, then skyrocketed by 78.11% to -$1.5 million in 2023, then skyrocketed by 123.42% to $360000.0 in 2024, then soared by 333.89% to $1.6 million in 2025.
  • Its Change in Cash stands at $1.6 million for Q3 2025, versus -$633000.0 for Q2 2025 and $407000.0 for Q1 2025.